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Abstract
Background: The problem of inappropriate use of antibiotics and the resulting growth in antimicrobial resistance
(AMR) has implications for Poland and the world. The objective of this paper was to compare and contrast
antibiotic resistance and antibiotic utilisation in Poland in recent years versus other European countries, including
agreed quality indicators, alongside current AMR patterns and ongoing policies and initiatives in Poland to
influence and improve antibiotic prescribing.
Methods: A quantitative ten-year analysis (2007–2016) of the use of antibiotics based on European Centre for
Disease Prevention and Control (ECDC) data combined with a literature review on AMR rates and antimicrobial
stewardship initiatives.
Results: The system of monitoring AMR and appropriate strategies to address AMR rates remain underdeveloped in
Poland. The role of microbiological diagnostics and efforts to prevent infections is currently underestimated by
physicians. Overall, Poland had one of the highest rates of total consumption of antibiotics in the analysed
European countries. Total consumption of antibacterials for systemic use and relative consumption of beta-
lactamase sensitive penicillins were characterized by small but statistically significant average annual increases
between 2007 and 2016 (from 22.2 DIDs to 23.9 DIDs and from 0.8 to 1.3%, respectively).
Conclusions: The integrated activities around appropriate antibiotic prescribing in the pre- and post-graduate
training of physicians and dentists seem to be particularly important, as well as changes in policies on prescribing
antibiotics within ambulatory care. AMR and appropriate prescribing of antibiotics should be the focus of health
policy actions in Poland.
Keywords: Antibiotic consumption, Antimicrobial resistance, Antimicrobial resistance surveillance, European Union,
Health policy, Poland
Background
General
Antibiotics have significantly improved the prognoses of
patients with infectious diseases, reducing morbidity and
mortality. However, the use of antibiotics is invariably
associated with the risk of resistance development, with
numerous studies confirming the association between
increasing use of antibiotics and enhanced antimicrobial
resistance (AMR) [1–6]. Increasing AMR rates are not
helped by concerns regarding the choice of antibiotic or
duration of therapy, which can be incorrect in up to 50%
of cases [3, 7], as well as the extent of irrational prescrib-
ing of antibiotics for essentially viral infections [3], or
the increasing use of antibiotics in agriculture [7]. Acute
upper respiratory tract infections (URTIs), which are the
most common infections in ambulatory care, are essen-
tially viral in origin but with high rates of inappropriate
antibiotic use across countries [3, 8–10].
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As a result of growing concerns, we are seeing an in-
creasing number of programmes and activities across
countries, including European countries, to enhance ap-
propriate antibiotic use to reduce AMR rates. These in-
clude the development of Antimicrobial Stewardship
Program (ASP), as well as educational activities among
physicians and pharmacists [8, 11–17]. ASPs include
analysis of the consumption of antibiotics over time
alongside instigation and monitoring of activities to im-
prove appropriate use.
However, whilst the European Surveillance of Anti-
microbial Consumption (ESAC) network, and more re-
cently the European Centre for Disease Prevention and
Control (ECDC) [18, 19] and WHO Europe [20], have
researched antibiotic utilisation across Europe including
Poland, as well as assessed quality indicators for antibiotic
utilisation, there is currently limited patient-level data to
improve antibiotic prescribing in Poland. Physicians are
one of the key stakeholders to improve future antibiotic
use in Poland, with limited if any purchasing of antibiotics
without a prescription due to current restrictions.
We are aware of concerns with antibiotic prescribing
in Poland. A study published in 2008 showed that be-
tween 2002 and 2005, at least 64.3% of the studied popu-
lation were prescribed antibiotics [21]. Panasiuk et al.
reported that 78.5% of adults with acute URTIs had anti-
biotics as empirical first-line treatment [22]. Overall
anti-infectives (Anatomical Therapeutic Chemical class:
ATC J01-J07X) constituted approximately 5% of
pharmaceutical reimbursement in ambulatory care in
Poland in 2010, with amoxicillin with clavulanic acid
among the top 25 reimbursed medicines with the great-
est sales [23]. However, between 2004 and 2008, Poland’s
total antibiotic use was comparable to the median Euro-
pean level [24].
There have been initiatives in Poland to improve phys-
ician antibiotic prescribing through guidelines, with the
most recent guidelines published in 2016 [25]. However,
there have been concerns whether these have been prop-
erly disseminated and implemented, especially given
current individualism within the Polish healthcare sys-
tem, acceptance of authority (‘power distance’), and phy-
sicians wishing to avoid uncertainty [26]. In addition,
current short medical consultations do not allow for es-
tablishing a close relationship between physicians and
their patients, including educating patients regarding the
appropriate use of antibiotics. There are also concerns
with the lack of National Health Fund (NHF) activity to
improve the prescribing of antibiotics among physicians
in Poland unlike co-ordinated activities in, for instance,
the Republic of Srpska [14], as well as former Soviet
Union Republics, such as Azerbaijan [17].
There are also concerns with the rate of hospital ac-
quired infections in Poland [27], which need addressing
alongside generally improving antibiotic utilization in
Poland to reduce AMR rates.
Antimicrobial resistance patterns across Europe and
activities to reduce AMR
The gathering and analysis of information on drug re-
sistance of bacterial strains among European countries is
facilitated by the Healthcare-Associated Infections Sur-
veillance Network (HAI-Net) [28] within the European
Centre for Disease Prevention and Control (ECDC). De-
tailed data on drug resistance of selected bacterial strains
and groups of antibiotics are gathered within the Euro-
pean Antimicrobial Resistance Surveillance Network
(EARS-Net) [29].
As discussed, there are several ongoing activities
across countries to reduce rising AMR rates given on-
going concerns. Identified objectives within the WHO
Global Plan on Antimicrobial Resistance [30] included
sharing knowledge and evidence, as well as instigating
programmes to optimise antibiotic use through education
and other activities. This is particularly important in
Poland, where the incidence of various types of infections,
including surgical site infections [31] and bloodstream in-
fections associated with central venous catheters, appear
higher than in neighbouring countries [27].
We are aware there needs to be greater documentation
and discussions about current activities in Poland to im-
prove antibiotic use. This includes assessing the quality
of antibiotic use in ambulatory care against agreed indi-
cators, including the use of combination penicillins,
third- and fourth-generation cephalosporins, as well as
fluoroquinolones, as these are considered by the WHO
and others as critically important antibiotics to monitor
[20, 32, 33].
Consequently, the objective of this paper was to com-
pare and contrast antibiotic resistance and antibiotic
utilisation in Poland in recent years versus other Euro-
pean countries, including agreed quality indicators,
alongside current AMR patterns and ongoing policies
and initiatives in Poland to influence antibiotic prescrib-
ing. The findings will help guide the development of fu-
ture pertinent policies to improve antibiotic prescribing
in Poland, given current concerns.
Methods
A quantitative research was conducted on ECDC find-
ings and combined with a literature review to document
current antibiotic resistance rates in Poland, as well as
initiatives to improve antibiotic prescribing. The litera-
ture review was not a systematic review; however, it in-
cluded most cited expert publications. Simple statistical
analyses were performed to help identify any trends
where pertinent. We have used such approaches in pre-
vious publications to assess the influence of current
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antibiotic strategies as well as help plan future activities
[13, 14, 16, 17]. Table 1 presents the measures which
were used to assess the quality of antibiotic prescribing
in Poland, in ambulatory care, during the past 10 years
(i.e. from 2007 to 2016) based on ECDC, WHO and
other suggested indicators among the J01 ATC class [19,
21, 32–34]. Linear regression analysis was used to assess
any significant changes in the trends of the quality indi-
cator measures (continuous variable) over the study
period from 2007 to 2016; hence five regression models
were conducted; one model per each quality indicator
measure, but with time as the independent factor in all
of the five models.
Ambulatory care, including general practitioner pre-
scribing and out-patient dispensing (children and
adult patients), was chosen for comparative purposes,
as this contains the highest proportion of antibiotic
use in Poland. In 2016, antibiotic consumption was
23.98 Defined Daily Doses per 1000 inhabitants per
day (DIDs) within ambulatory (community) care,
while only 1.36 DIDs within hospital sector [19]. In
addition, comparative figures are available across Eur-
ope in recent years via ECDC. The only exceptions
are Cyprus and Romania, where the authorities pro-
vided total consumption data, i.e. including in-patient
use, as they were unable to separate out the different
components.
The findings for Poland in 2016 were also compared
with other European countries including those with the
highest and lowest values for each indicator, with a spe-
cial emphasis on neighbouring CEE countries, to again
provide future guidance. Descriptive statistics were used
to summarise the study variables. Univariate linear re-
gression was used to evaluate any annual trend change
in the study outcomes during the study period.
Results
Specific actions to prevent AMR in Poland
The coordinated system of monitoring AMR rates
among patients in Poland has been implemented since
1997 with the establishment of the National Reference
Centre for Antimicrobial Susceptibility Testing (NRCAST).
Since 2002, information on antimicrobial utilisation across
sectors, including hospitals and ambulatory care, has also
been gathered via NRCAST. This organisation is also in
charge of identification and susceptibility testing of bacterial
strains from serious and difficult to diagnose infections,
with a special focus on certain pathogens such as
Methicillin-resistant Staphylococcus aureus (MRSA), and
monitoring of the spread of resistant strains in hospitals
and ambulatory care across Poland. NRCAST also provides
data to the European Antimicrobial Resistance Surveillance
Network (EARSS-Net) as well as ECDC.
In 2004, the Ministry of Health (MoH) established the
National Programme for the Protection of Antibiotics
(NPPA) coordinated by the National Institute of Medi-
cines. with the main goal: to monitor AMR in Poland.
The MoH is also the main stakeholder in charge of pol-
icy development to help prevent or reduce AMR in
Poland as well as providing the legal framework for hos-
pital infection control. The Chief Sanitary Inspectorate
is responsible for suggesting potential initiatives where
concerns exist. In practice, activity of the MoH in the
area of AMR monitoring and prevention has been lim-
ited, principally left to the State Consultant for Micro-
biology and the Chief Sanitary Inspectorate to formulate
policies on AMR. As far as the NHF’s involvement is
concerned, usually only limited activities have been
undertaken to date to help improve antibiotic use with
appreciable autonomy among physicians. Having said
this, pneumococcal vaccination became compulsory in
Table 1 Indicators used to assess the quality of antibiotic prescribing
Indicator’s description Indicator’s acronym or shortened name
Consumption of antibacterials for systemic use (J01) expressed in defined daily doses
per 1000 inhabitants per day (DIDs)
Total consumption J01
Consumption of beta-lactamase sensitive penicillins (J01 CE) expressed as percentage
of the total consumption of antibacterials for systemic use (J01); i.e. relative consumption
of beta-lactamase sensitive penicillins
J01 CE%
Consumption of combination of penicillins, including beta-lactamase inhibitor (J01CR)
expressed as percentage of the total consumption of antibacterials for systemic use (J01);
i.e. relative consumption of combination of penicillins, including beta-lactamase inhibitor
J01CR%
Consumption of third- and fourth-generation cephalosporins (J01(DD + DE)) expressed as
percentage of the total consumption of antibacterials for systemic use (J01); i.e. relative
consumption of third- and fourth-generation cephalosporins
J01DD + DE%
Consumption of fluoroquinolones (J01MA) expressed as percentage of the total
consumption of antibacterials for systemic use (J01); i.e. relative consumption
of fluoroquinolones
J01MA%
Ratio of the consumption of broad-spectrum (J01(CR + DC + DD+(F-FA01))) to the
consumption of narrow-spectrum penicillins, cephalosporins and macrolides
(J01(CE + DB + FA01))
J01B/N%
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Poland in January 2017. The roles of other Polish health
care system stakeholders in policy formulation to pre-
vent or reduce AMR are principally advisory ones.
Current resistance patterns in Poland
Infections in Polish patients illustrate the relationship
between high utilisation and high levels of resistance, i.e.
the high consumption of trimethoprim and sulfameth-
oxazole [35] has been accompanied by high levels of
antibiotic resistance [5]. Having said this, the prevalence
of MRSA in Poland in 2013 was 16%, with prevalence
rates exceeding 25% in many EU Member States [35].
Concerns with current AMR rates in Poland are con-
firmed by data on Acinetobacter baumannii infection
(ACI), which are some of the most important opportun-
istic pathogens responsible for the most severe infections
characterised by the high level of resistance to com-
monly used antibiotics. More than 75% of ACI strains of
A. baumannii isolated from pneumonia cases among
hospitalised patients in southern Poland were resistant
to 14 out of 16 antimicrobials tested [36], with approxi-
mately 60% of A. baumannii strains from patients with
invasive infections, pneumonia, bloodstream infections
and meningitis, resistant to all antimicrobials tested with
the exception of colistin. The extensively-drug resistant
strains accounted for 80.8% of isolates tested [37]. The
largest AMR outbreak in Poland in recent years was ob-
served between 2012 and 2014 in two major cities
(Warsaw and Poznan). It concerned New Delhi
metallo-β-lactamase (NDM)-producing Enterobacteria-
ceae. Out of 374 cases of infection/colonisation with
NDM-positive Enterobacteriaceae identified in that
period, 370 cases were associated with a Klebsiella pneu-
moniae outbreak [38].
Concerns with AMR are exacerbated by the fact that
the current surveillance systems in Poland do not cur-
rently function optimally. Examples include concerns
with data on MRSA epidemiology both in the general
population of hospitalised patients, as well as new-borns
with very low birth weight [39]. Interestingly, along with
a high level of MRSA prevalence at 15% among adult
patients in general hospitals, considerable heterogeneity
of strains has been detected.
Empiric use of antibiotics vs. routine testing as well as
prevention
Efforts in Poland to contain AMR should ideally rely on
microbiological tests to guide current treatment as well
as provide guidance on optimal empiric treatment when
the need arises. A good example is the Polish Neonato-
logical Network where data is gathered from Neonatal
Intensive Care Units (NICU) on infection surveillance
among newborns with very low birth weights [39]. The
analysis of antibiotic utilisation in MRSA infections
compared with methicillin-sensitive Staphylococcus aur-
eus (MSSA) infections revealed that average therapy du-
rations were 11.2 and 12.3 days respectively [39].
Concurrently, the level of glycopeptides’ use was high in
both MRSA and MSSA infections, providing a rationale
for the introduction of quick molecular tests into routine
clinical practice, especially in NICUs [40].
Despite situations such as this, the role of microbio-
logical diagnostics to reduce empiric use of antibiotics as
well as efforts to prevent infection is currently underesti-
mated by physicians in Poland [38, 41, 42]. Nowadays,
there is a greater focus on treatment rather than preven-
tion, since in Poland, unlike some Western European
countries, diagnostic laboratories are organised separ-
ately from hospital structures, with most microbiologists
not directly involved in treatment decisions. This is par-
ticularly problematic for nosocomial infections.
In addition, usually health care providers (hospitals,
family physicians) must pay for microbiologic diagnostic
tests from their budgets and ambulatory care patients
must pay for tests out of pocket. Both of these can be a
concern. Consequently, most community acquired infec-
tions are currently treated empirically.
Quantitative analysis of antibiotic prescribing quality
indicators in ambulatory care
Table 2 contains details of the pertinent antibiotic pre-
scribing quality indicators in ambulatory care in Poland
Table 2 Key ambulatory care antibiotic prescribing quality indicators for Poland 2007 to 2016
Indicator – ECDC code 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 P-value* % change 2016/2007
Total utilisation J01 22.2 20.8 23.6 21.1 21.1 22.9 23.6 22.8 26.2 23.9 0.0357 8.3
J01 CE% 0.8% 0.8% 0.6% 0.7% 0.5% 0.7% 0.7% 0.9% 1.3% 1.3% 0.0391 62.5
J01CR% 18.7% 21.7% 20.9% 21.3% 30.3% 16.9% 16.5% 16.6% 17.0% 18.5% 0.2949 −1.07
J01DD + DE% < 0.1% < 0.1% < 0.1% < 0.1% < 0.1% < 0.1% < 0.1% < 0.1% < 0.1% < 0.1% NA
J01MA% 5.2% 5.8% 5.3% 5.8% 5.6% 5.3% 5.0% 5.3% 5.3% 5.9% 0.9867 13.5
J01B/N% 30.3% 32.5% 36.3% 37.1% 57.6% 36.9% 34.9% 29.0% 24. 8% 25.8% 0.3771 −14.9
Note: *p-value obtained from the linear regression model
Legend: explanation of acronyms is provided in Table 1
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during the past 10 years. Total consumption of antibacte-
rials for systemic use and consumption of fluoroquino-
lones expressed as percentage of the total consumption of
antibacterials for systemic use (i.e. relative consumption of
fluoroquinolones) were characterized by small increases
between 2007 and 2016 (8.3 and 13.5%, respectively), with
a significant average annual increase of 3.6% (p = 0.0357)
for total antibiotic consumption. Relative consumption of
beta-lactamase sensitive penicillins revealed a much bigger
increase in the analyzed period (62.5%), with a significant
average annual increase of 0.0006% (p = 0.0391). The rela-
tive consumption of combination of penicillins, including
beta-lactamase inhibitor, as well as a ratio of the con-
sumption of broad-spectrum to the consumption of
narrow-spectrum penicillins, cephalosporins and macro-
lides decreased in the analyzed period by 1.07 and 14.9%
respectively.
The total consumption of antibiotics in the surveyed
European countries ranged in 2016 from 10 DIDs in the
Netherlands to 36 DIDs in Greece (median 12 DIDs),
while Poland had one of the highest consumption rates,
exceeding the European median (expressed in DIDs)
more than twice (Fig. 1). Only some countries of South-
ern Europe had higher consumption rates, while in the
remaining 78.3% countries the consumption rates were
lower than in Poland.
However, interpretation of the other assessed indices does
not bring unequivocally negative conclusions. There has
been a sizeable increase in consumption of beta-lactamase
sensitive penicillins (J01 CE) from a very low share of total
antibiotic consumption in previous years (Table 2). The
current share of these antibiotics in treatment is on a not-
ably low level when compared with other European
countries (Fig. 2). Encouragingly, the consumption of com-
bination penicillins (J01CR), third- and fourth-generation
cephalosporins (J01(DD +DE)) and fluoroquinolones
(J01MA) is on a relatively low level (Figs. 3, 4, 5). Poland is
among the European countries with the lowest share of
these antibiotics within overall antibiotic consumption, es-
pecially with regard to third- and fourth-generation cepha-
losporins. On the other hand, in ambulatory care
wide-spectrum antibiotics are used relatively more often
(ratio J01(CR +DC+DD+(F-FA01) to J01(CE +DB +
FA01)) – Fig. 6 (explanation of acronyms is provided in
Table 1, see also Abbreviations). However, the situation has
improved in comparison to the past years. In 2007 the
share of wide-spectrum antibiotics was 30.3%, while in
2016 it was 25.8% (Table 2).
Discussion
There is currently a variable situation regarding anti-
biotic prescribing in Poland. Poland is at the high end of
antibiotic utilization in recent years; at almost 24 DIDs
in 2016, appreciably higher than Estonia, Latvia or
Slovenia. In addition, consumption grew significantly by
about 8% between 2007 and 2016; however, appreciably
lower than the 36% increase in total worldwide antibiotic
consumption during the past decade [6]. There are also con-
cerns with the low level of prescribing of beta-lactamase
sensitive penicillins in Poland, compared for instance with
Slovakia, Finland, Slovenia or Sweden. However, encour-
agingly prescribing rates for these penicillins have been
growing in recent years. Encouragingly as well, there was
relatively low consumption of combination penicillins and
third- and fourth-generation cephalosporins in Poland, with
a slight decrease over the years.
There was also a relatively low level of fluoroquinolone
consumption in Poland versus other European countries
(at 5.9% in 2016). However, there are concerns regarding
the growth of fluoroquinolone prescribing in Poland in re-
cent years, expressed as a percentage of the total antibiotic
consumption (Table 2). The use of fluoroquinolones, due
Fig. 1 Ambulatory care antibiotic consumption across Europe in 2016 in DIDs. Legend: DIDs - Defined Daily Doses per 1000 inhabitants per day;
*only total consumption data available
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to their numerous side effects, should be limited to situa-
tions where there are no other therapeutic options avail-
able. One of the most important side effects of the use of
fluoroquinolones is (among others) Clostridium difficile
infections (CDI) [11]. The Polish hospitals reported almost
the highest crude incidence density of community-
associated CDI incidence densities (1.4 cases/10,000
patient-days) in Europe (EU/EEA mean was only 0.8
cases/10,000 patient-days) [43]. Consequently, there is an
urgent need to educate physicians in Poland about the ap-
propriate use of fluoroquinolones, unless this is a conse-
quence of high antimicrobial resistance in Poland to other
antibiotics. This will be investigated further in future re-
search projects.
There are also concerns at the extent of prescribing of
broad versus narrow spectrum antibiotics in Poland,
their consumption ratios in 2016 being very high level at
25.81% of total antibiotic consumption versus for in-
stance 0.68% in Finland. Fortunately, this ratio is de-
creasing in Poland.
This variable picture regarding current antibiotic utilisa-
tion patterns in Poland may well reflect the relative lack of
educational activities by the NHF and the MoH among
physicians. We do know that there is a lack of prepared-
ness among physicians in Poland for educational activities
in the field of rational antibiotic therapy. In addition, we
are aware that research in area of medical education has
shown that problem-based learning curricula are rarely in-
troduced in a country with a high ‘power distance’ and
‘uncertainty avoidance’, which currently includes Poland
[44]. This is confirmed by both high total consumption
antibiotics versus other European countries and a high
proportion (ratio) of broad-spectrum antibiotics. The no-
tion of power distance refers to the degree of hierarchy in a
Fig. 2 Consumption of beta-lactamase sensitive penicillins (J01 CE) expressed as percentage of total antibacterial consumption in 2016
Fig. 3 Consumption of combination penicillins, including beta-lactamase inhibitors (J01CR), expressed as percentage of total antibacterial
consumption in 2016
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country and it has been defined by Hofstede as the extent
to which the less powerful members of organizations and
institutions accept and expect that power is distributed un-
equally [45]. The notion of uncertainty avoidance deals with
a society’s tolerance for uncertainty and ambiguity. A higher
score indicates that people feel uncomfortable in novel, un-
known or surprising situations [45].
Overall, integrated activities around appropriate anti-
biotic prescribing in the pre- and post-graduate training
of physicians and dentists should be particularly import-
ant. Currently, the concept of antimicrobial stewardship
(AMS) is not included in the curricula of studies and
specializations except for specialization for microbiolo-
gists. However, in the Polish health care system there are
very few physicians-microbiologists (only 110 profes-
sionally active in 2018). There could also be the involve-
ment of other specialists in hospitals, such as hospital
pharmacists, as part of Drugs and Therapeutic Commit-
tees helping with the implementation and monitoring of
AMS programs [46].
Other direct measures, which could be recommended
for implementation in Poland, include the introduction
of limitations in antibiotic prescribing within ambulatory
care in Poland, through their stratification, similar to the
Republic of Srpska (Bosnia and Herzegovina) or
Slovenia, or a basic positive list of medicines with refer-
ence prices and a supplementary list which includes
more expensive medicines [13, 16]. In the Republic of
Srpska amoxicillin, benzathine-phenoxymethylpenicillin,
cefalexin, doxycycline, erythromycin, phenoxymethylpe-
nicillin, and sulfamethoxazole with trimethoprim are re-
imbursed between 90 to 100%; with norfloxacin
reimbursed 50%; with 100% co-payment for all other an-
tibiotics [16]. In Slovenia, the national health insurance
Fig. 4 Consumption of third- and fourth-generation cephalosporins (J01DD + DE) expressed as percentage of total antibacterial consumption
in 2016
Fig. 5 Consumption of fluoroquinolones (J01MA) expressed as percentage of total antibacterial consumption in 2016
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company has instigated prescribing restrictions for
amoxicillin/clavulanic acid, third-generation cephalospo-
rins, fluoroquinolones and the macrolides together with
their place in therapy i.e., first, second or third line, to
enhance antibiotic prescribing [13]. Such activities can
potentially be applied in Poland to reduce excessive pre-
scribing of broad-spectrum antibiotics.
Promoting and spreading knowledge on antibiotics, as
medicines designated for combatting bacterial infections
but ineffective against viruses, is urgently needed. The
education campaigns should be targeted not only at physi-
cians, but also patients, especially because other factors
should be taken into consideration. These include the rela-
tive cost of prescribed antibiotic and the cost of medical
consultations. Educational programmes, including aca-
demic detailing and providing decision support systems,
have improved antibiotic use, although some of the results
have been modest [8, 47, 48]. Feedback to physicians, espe-
cially high prescribers of antibiotics, has also worked well
[49]. Enhancing physician communication skills, as well as
the availability of point-of-care testing, can also reduce in-
appropriate prescribing of antibiotics for acute respiratory
tract infections [50, 51]. Although not confirmed by pro-
spective studies, it might be expected that in countries
where medical consultations and the cost of antibiotics is
high, there will be a lower likelihood for excessive use of
antibiotics. Unfortunately, from this perspective, prices of
commonly prescribed antibiotics are usually low in Poland,
which may result in increased consumption and secondary
antibiotic resistance. In contrast, ambulatory patients usu-
ally must pay out-of-pocket for microbiological diagnostic
tests, which are very often more expensive than prescribed
antibiotics. This may result in underutilization of diagnos-
tic testing due to financial reasons.
Consequently, other avenues will be important for im-
proving antibiotic utilization. The provision of health
services is overwhelmingly focused on the treatment of
infections rather than their prevention in Poland. This
applies to many elements of infection control pro-
grammes, regarding both nosocomial and non-hospital in-
fections. Notably, hand hygiene should be mentioned,
since the existing level of knowledge of its rules is not suf-
ficient among medical personnel and the compliance with
recommendations is rather low in Poland. Intensive edu-
cational campaigns, addressed to both medical and social
workers, are highly required. The more specific proce-
dures, aiming to prevent certain forms of infections (e.g.
‘bundle strategies’ for prevention of device-associated in-
fections in intensive care units, including small sets of
evidence-based practices which have been proven to im-
prove patient outcomes, when applied together) should be
actively promoted and implemented. A more effective
interdisciplinary education and cooperation between phy-
sicians and staff of microbiological laboratories are neces-
sary, and implementation of fast and modern diagnostic
methods is crucial. AMR surveillance is largely under-
developed, and the scale of AMR in Poland may be under-
estimated. This is despite a relatively high consumption of
antibiotics and some alarming trends for certain bacterio-
logical strains. These are considerations for the future.
Conclusions
Whilst the coordinated system of monitoring AMR rates
in Poland was initiated almost 20 years ago, it remains
underdeveloped, similarly to appropriate strategies to ad-
dress AMR. The role of microbiological diagnostics, and
efforts to prevent infections, is currently underestimated
by physicians, who put a greater emphasis on treatment
rather than prevention.
Total consumption of antibacterials for systemic use
and relative consumption of beta-lactamase sensitive
penicillins were characterized by small but statistically
significant average annual increases between 2007 and
2016. Overall, Poland has one of the highest rates of
Fig. 6 Consumption of broad-spectrum (B) to narrow-spectrum (N) antibiotics in 2016 (ratio B vs N)
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total consumption of antibiotics among European coun-
tries. Although indicators such as the prevalence of
MRSA are within the average values observed in the EU,
in case of P. aeruginosa, K. pneumoniae and Acinetobac-
ter there is over 50% resistance to fluoroquinolones, in
invasive infections cases in Poland (highest prevalence
rates among the EU countries).
Since the limited educational activities among physi-
cians and dentists may play an important role in the
current antibiotic consumption patterns, integrated ac-
tions focusing on appropriate antibiotic prescribing in
the pre- and post-graduate training should be instigated
and followed up at national level. The introduction of
limitations in antibiotic prescribing within ambulatory
care, through their stratification, is also recommended.
Education campaigns targeted also to patients are ur-
gently needed as well. Overall, taking actions to improve
antibiotic utilisation should be in focus of health policy
actions in Poland.
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